|
May 11
|
Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)
|
|
May 9
|
Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
|
|
May 7
|
Altimmune to Participate at Two Upcoming Investor Conferences
|
|
May 2
|
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
|
|
May 1
|
Altimmune to Participate at Two Upcoming Conferences
|
|
Apr 25
|
Altimmune Statement on the Passing of Dr. Stephen Harrison
|
|
Mar 27
|
Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Mar 20
|
Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
|
|
Jan 2
|
Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024
|
|
Nov 30
|
Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide
|
|
Nov 7
|
Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update
|
|
Aug 3
|
Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
|